Screener
Recursion Pharmaceuticals, Inc. RXRX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Recursion Pharmaceuticals, Inc.’s reported figures.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
FAQ
- What is Recursion Pharmaceuticals, Inc.'s free cash flow?
- Recursion Pharmaceuticals, Inc. (RXRX) reported free cash flow of -$105.99M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s free cash flow changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s free cash flow decreased by 33.2% year-over-year, from -$79.57M to -$105.99M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s free cash flow?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s free cash flow has grown at a 17.5% compound annual growth rate (CAGR), from -$198.41M to -$378.28M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Recursion Pharmaceuticals, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude